ASCO GI 2021 | KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC
Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, provides an update on the progression-free survival (PFS) analysis of the KEYNOTE-177 study (NCT02563002), a Phase III trial evaluating the activity of pembrolizumab versus chemotherapy as a first-line approach for patients with microsatellite-instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). While overall survival analysis is ongoing, pembrolizumab demonstrated significantly improved PFS, reduced incidence of treatment-related adverse events, and resulted in an improved health-related quality of life score. Furthermore, despite crossover, PFS2 (time from randomization to progression on next line of therapy or any cause death) was superior in patients treated initially with pembrolizumab. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Honoraria from Bristol-Myers Squibb, Guardant Health, Innovent Biologics, Merck KGaA, Merck Sharp and Dohme, Roche
Consultant or Advisory Role from Merck Sharp and Dohme, Roche,
Research Funding from Bristol-Myers Squibb (Inst), Gilead Sciences (Inst), Merck KGaA (Inst), Merck Sharp and Dohme (Inst), Roche (Inst)
Travel, accommodations and expenses from Innovent Biologics, Merck KGaA, Roche
